

15992 US PTO  
012604

UTILITY  
PATENT APPLICATION  
TRANSMITTAL

Attorney Docket No.	PC25051A
First Inventor	ATSUO KUKI
Title	HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE
Express Mail Label No.	EV291841927US

(Only for new nonapplications under 37C.F.R. §1.53(b))

**APPLICATION ELEMENTS**  
See MPEP chapter 600 concerning utility patent application contents.

**ADDRESS TO:** Mail Stop Patent Applications  
Commissioner for Patents  
Box 1450  
Alexandria, VA 22313-1450

- ☒ Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit an original, and a duplicate for fee processing)
- ☐ Applicant claims small entity status  
See 37 CFR 1.27
- ☒ Specification [Total Pages 54]  
(preferred arrangement set forth below)
  - Descriptive title of the invention
  - Cross References to Related Applications
  - Statement Regarding Fed sponsored R&D
  - Reference to sequence listing, a table, or a computer program listing appendix
  - Background of the invention
  - Brief Summary of the invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
- ☐ Drawing(s) (35 U.S.C. 113) [Total sheets \_\_\_\_\_]
- ☒ Oath or Declaration [Total pages 3]
  - ☒ Newly executed (original or copy)
  - ☐ Copy from a prior application (37 CFR §1.63(d))  
(for continuation/divisional with Box 18 completed)
    - ☐ **DELETION OF INVENTOR(S)**  
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
- ☒ Application Data Sheet. See 37 CFR 1.76

- ☐ CD-ROM or CD-R in duplicate, large table or computer Program (Appendix)
- Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
  - ☐ Computer Readable Copy (CRF)
  - Specification Sequence Listing on:
    - ☐ CD-ROM or CD-R (2 copies)
    - ☐ Paper
  - ☐ Statement verifying identity of above copies

**ACCOMPANYING APPLICATION PARTS**

- ☒ Assignment Papers (cover sheet & document(s))
- ☐ 37 CFR 3.73(b) Statement ☒ Power of Attorney  
(when there is an assignee)
- ☐ English Translation Document (if applicable)
- ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
- ☐ Preliminary Amendment
- ☒ Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
- ☐ Certified Copy of Priority Document(s)  
(if foreign priority is claimed)
- ☐ Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
- ☐ Other:

18. If a **CONTINUING APPLICATION**, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37CFR 1.76.

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: \_\_\_\_\_ / \_\_\_\_\_

Prior application information: Examiner \_\_\_\_\_ Group/Art Unit: \_\_\_\_\_

For CONTINUATION OR DIVISIONAL APPS only; The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts

**19. CORRESPONDENCE ADDRESS**

☒ Customer Number 28940 or ☐ Correspondence address below

Name			
Address			
City	State	Zip Code	
Country	Telephone	Fax	

NAME (Print/type)	Keith D. Hutchinson	Registration No. (Attorney/Agent)	43,687
Signature	<i>Keith D. Hutchinson</i>	Date	January 26, 2004

This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for

19270 U.S. PTO  
10/765227  
012604

# FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

☐ Applicant claims small status. See 37 CFR 1.27

Total Amount of Payment \$824.00

## Complete if Known

Application Number	To be assigned
Filing Date	Herewith
First Named Inventor	ATSUO KUKI
Examiner Name	To be assigned
Art Unit	To be assigned
Attorney Docket No.	PC25051A

## METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit  
Account  
Number  
Deposit  
Account  
Name

500329

Agouron Pharmaceuticals, Inc.

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments  
☒ Charge any additional fee(s) or any underpayment of fee(s)

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

## FEE CALCULATION

### 1. BASIC FILING FEE

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1001	770	2001	385	Utility filing fee	770
1002	340	2002	170	Design filing fee	
1003	530	2203	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	filing fee	

Subtotal (1)s \$ 770

### 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Extra Claims Fee from below Fee Paid

Total Claims	23	- 20** =	3	x	18	=	54
Independent Claims	2	- 3 =	-1	x	0	=	0
Multiple Dependent				x	0	=	0

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description
1202	18	2202	9	Claims in excess of 20
1201	86	2201	43	Independent claims in excess of 3
1203	290	2203	145	Multiple dependent claim, if not paid
1204	86	2204	43	**Reissue independent claims over original patent
1205	18	2205	9	**Reissue independent claims over original patent

(\$) 54

\*\*or number previously paid, if greater; For Reissues, see above

## 3. ADDITIONAL FEES

Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Description	Fee Paid
		1051	130	2051 65	Surcharge - late fee or oath
		1052	50	2052 25	Surcharge-late filing fee or cover sheet
		1053	130	1053 130	Non-English specification
		1812	2,520	1812 2,520	Forfeiting a request for Ex Parte reexamination
		1804	920*	1804 920*	Requesting publication of SIR prior to Examiner action
		1805	1,840*	1805 1,840*	Requesting publication of SIR after Examiner action
		1251	110	2251 55	Extension for reply within first month
		1252	420	2252 210	Extension for reply within second month
		1253	950	2253 475	Extension for reply within third month
		1254	1,480	2254 740	Extension for reply within fourth month
		1255	2,010	2255 1,005	Extension for reply within fifth month
		1401	330	2401 165	Notice of Appeal
		1402	330	2402 165	Filing a brief in support of an appeal
		1403	290	2403 145	Request for oral hearing
		1451	1,510	1451 1,510	Petition to institute a public use proceeding
		1452	110	2452 55	Petition to revive unavoidable
		1453	1,330	2453 665	Petition to revive - unintentional
		1501	1,330	2501 665	Utility issue fee (or reissue)
		1502	480	2502 240	Design issue fee
		1503	640	2503 320	Plant issue fee
		1460	130	1460 130	Petitions to the Commissioner
		1807	50	1807 50	Processing fee under 37 CFR 1.17(q)
		1806	180	1806 180	Submission of Information Disclosure Stmt
		8021	40	8021 40	Recording each patent assignment per property (times number of properties)
		1809	770	2809 385	Filing a submission after final rejection (37 CFR 1.129(a))
		1810	770	2810 385	For each additional invention to be examined (37 CFR 1.129(b))
		1801	770	2801 385	Request for Continued Examination (RCE)
		1802	900	1802 900	Request for expedited examination of a design application

Other Fee (specify) \_\_\_\_\_

\*Reduced by Basic Filing Fee Paid

Subtotal (3)

(\$) 0

## SUBMITTED BY

(Complete if applicable)


Name (Printed/Type)	Keith D. Hutchinson	Registration No.	43,687	Telephone	858-526-4608
Signature	Keith D. Hutchinson	(Attorney Agent)			

Warning: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.  
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.  
If you need assistance in completing the form, call 1-800-pto-9199 and select option 2.

PC25051A  
Non-Provisional Patent Application

Certificate of Mailing (37 C.F.R. §1.10);  
I hereby certify that this correspondence is being  
deposited with the United States Postal Service as  
Express Mail (EV291841927US) in an envelope  
addressed to: Mail Stop: Patent Applications,  
Commissioner for Patents,  
PO Box 1450, Alexandria, VA 22313-1450  
on this 26th day of January 2004.

s/   
Rachel Potash

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**In re the Application of:**  
**ATSUO KUKI, et al.**

**Serial No.: Not Yet Assigned**

**Filed: Herewith**

**For: HIV INTEGRASE INHIBITORS,  
PHARMACEUTICAL COMPOSITIONS, AND  
METHODS FOR THEIR USE**

**Group Art Unit: Not Yet Assigned**

**Examiner: Not Yet Assigned**

Mail Stop: Patent Applications  
Honorable Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


**TRANSMITTAL LETTER**

Transmitted herewith are the following documents:

- |   |                     |
|---|---------------------|
| 1. Utility Patent Application Transmittal | 1 page;             |
| 2. Fee Transmittal                        | 1 page + duplicate; |
| 3. Copy of Assignment Papers              | 10 pages;           |
| 4. Application Data Sheet                 | 2 pages;            |
| 5. Specification                          | 54 total pages;     |
| • Claims                                  | 5 pages;            |
| • Abstract                                | 1 page;             |
| 6. Power of Attorney                      | 5 pages;            |
| 7. Declaration for Utility                | 3 pages;            |
| 8. Return Postcard                        | 1 postcard; and     |
| 9. Total Fee Due                          | Deposit Account .   |

Respectfully submitted,

Date: Jan. 26, 2004

  
Keith D. Hutchinson  
Attorney For Applicants  
Registration No. 43,687

Agouron Pharmaceuticals, Inc./A Pfizer Company  
Patent Department  
10777 Science Center Drive  
San Diego, California 92121  
Phone: (858) 526-4608  
Fax: (858) 678-8233